HW241045 / Humanwell Healthcare - LARVOL DELTA

A Phase I Study of HW241045 in Healthy Subjects (clinicaltrials.gov) - P1 | N=102 | Not yet recruiting | Sponsor: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.

New P1 trial • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

A Phase Ia Clinical Trial of HW241045 (clinicaltrials.gov) - P1 | N=56 | Recruiting | Sponsor: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.

New P1 trial • Idiopathic Pulmonary Fibrosis

Recently, Wuhan Renfu Innovative Drug R&D Center Co., Ltd., a subsidiary of Renfu Pharmaceutical Group, obtained the “Drug Clinical Trial Approval Notice“ for HW241045 tablets approved and issued by the National Medical Products Administration, approving the conduct of clinical trials for the treatment of idiopathic pulmonary fibrosis [Google translation] (bydrug.pharmcube.com)

New trial • Idiopathic Pulmonary Fibrosis